Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 7 of 7 results for somatropin

  1. Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth failure in children.

  2. Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth hormone deficiency in adults.

  3. Somatrogon for treating growth disturbance in children and young people aged 3 years and over (TA863)

    Evidence-based recommendations on somatrogon (Ngenla) for treating growth disturbance in children and young people aged 3 years and over.

  4. Somapacitan for treating growth hormone deficiency in children [ID6178]

    In development [GID-TA11153] Expected publication date: TBC

  5. Macimorelin for diagnosing growth hormone deficiency (MIB320)

    NICE has developed a medtech innovation briefing (MIB) on macimorelin for diagnosing growth hormone deficiency .

  6. Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)

    Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin (Copegus) for treating chronic hepatitis C in children and young people.

  7. NICE recommends a weekly injection for treating growth failure in children

    This recommendation comes from a pilot to develop simpler, faster evaluations for the appraisal of some treatments.